Login
bluebird bio, Inc. NASDAQ: BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
| Name | bluebird bio, Inc. |
| Ticker | BLUE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
30.67
25.62 / 70.98 |
| Momentum | Neutral |
| Market cap | 2.1 B |
| 1Y Total Return |
-47.03%
Weak |
| 1Y Volatility |
70.01%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
Details
| Ticker | BLUE |
| Name | bluebird bio, Inc. |
| ISIN | US09609G1004 |
| CUSIP | 09609G100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 5/18/21
| Close Price | 30.67 |
| 52W Low/High | 25.62 / 70.98 |
| Market cap | 2.1 B |
| 1Y Total Return |
-47.03%
Weak |
| 1Y Volatility |
70.01%
High Risk |
| Beta | 2.50 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -257.3% |
| Cash from Op. / Cur. Liabilities | -2.27 |
| Diluted Earnings / Share | -9.43 |
| ROE | - |
| ROIC | -63.2% |
| Price / Revenue | 8.5 |
| Price / Book | 1.7 |
| Price / CF | -4.4 |
| Current Ratio | 5.3 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.17 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
242
|
54
|
51
|
45
|
11
|
9
|
|
| Gross Profit |
235
|
50
|
50
|
43
|
11
|
9
|
|
| R&D |
588
|
614
|
474
|
315
|
218
|
152
|
|
| EBITDA |
-608
|
-840
|
-611
|
-365
|
-272
|
-190
|
|
| Operating Income |
-654
|
-848
|
-624
|
-380
|
-276
|
-198
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
67
|
56
|
55
|
50
|
41
|
37
|
|
| EPS exc. Extra |
-9.43
|
-14.96
|
-11.36
|
-8.34
|
-7.22
|
-5.56
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
1,637
|
1,529
|
2,139
|
1,867
|
1,073
|
979
|
|
| Cash, Eq & Invt ShortTerm |
1,012
|
911
|
1,322
|
1,122
|
634
|
553
|
|
| Total Current Assets |
1,098
|
967
|
1,365
|
1,164
|
667
|
561
|
|
| Total Non-Current Assets |
540
|
562
|
774
|
703
|
405
|
418
|
|
| Intangibles |
25
|
26
|
25
|
29
|
33
|
37
|
|
| Total Liabilities |
437
|
409
|
367
|
297
|
257
|
172
|
|
| Total Current Liabilities |
206
|
184
|
147
|
108
|
73
|
39
|
|
| Long Term Debt |
231
|
224
|
220
|
189
|
185
|
133
|
|
| Shareholder equity |
1,200
|
1,120
|
1,772
|
1,570
|
815
|
807
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-468
|
-616
|
-459
|
-314
|
-228
|
-111
|
|
| Depreciation |
20
|
19
|
17
|
15
|
10
|
8
|
|
| Cash from Investing |
12
|
769
|
-452
|
-577
|
-2
|
-314
|
|
| Capex |
26
|
62
|
68
|
44
|
50
|
10
|
|
| Cash from Financing |
550
|
12
|
676
|
1,131
|
258
|
485
|
|
| Stock Issued |
550
|
12
|
677
|
1,105
|
244
|
485
|
|
| Debt (LT) Issued |
0
|
0
|
-1
|
-1
|
0
|
0
|
|
| Free Cash Flow |
-685
|
-325
|
-1,082
|
-642
|
-345
|
-359
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.3
|
5.2
|
9.3
|
10.8
|
9.2
|
14.4
|
|
| Financial Leverage D/E |
0.17
|
0.18
|
0.10
|
0.10
|
0.18
|
0.09
|
|
| Return on Capital Avg |
-63.2%
|
-62.0%
|
-40.9%
|
-36.4%
|
-36.7%
|
-35.8%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available